SCHEMBL23770749

SCHEMBL23770749

[O-][S+](Nc1ccc(C(F)(F)F)c(-c2ccccc2C(F)(F)F)n1)c1cccc(N2CC(O)C2)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 1/20 0.33
CYP1A2 P05177 2/20 0.31
CYP2C9 P11712 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
PDE10A Q9Y233 1/20 0.31
GRIN2B Q13224 1/20 0.31
SOS1 Q07889 1/20 0.31
PRKCA P17252 1/20 0.31
PRKCQ Q04759 1/20 0.31
TTR P02766 1/20 0.30
CLK2 P49760 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770744 0.85 RAF1 (0.33) MPLHCRTR1HCRTR2GRIN2BSOS1
SCHEMBL23770830 0.85 MAP4K1 (0.33) MPLHCRTR1HCRTR2GRIN2BSOS1
SCHEMBL23770733 0.82 PDE10A (0.32) HSD17B10HCRTR1HCRTR2PDE10AGRIN2B
SCHEMBL23770480 0.79 GRIN2B (0.33) GRIN2B
SCHEMBL23770787 0.79 PDE10A (0.35) CYP1A2CYP2C9KDM4EALDH1A1CYP3A4
SCHEMBL23770621 0.79 PDE10A (0.35) CYP1A2CYP2C9KDM4EALDH1A1CYP3A4
SCHEMBL23770649 0.78 PIM1 (0.34) CYP1A2CYP2D6TSHRPRKCQTTR
SCHEMBL23770812 0.78 HSD11B1 (0.30) SOS1
SCHEMBL19968850 0.77 SCN9A (0.37) MPLCYP1A2CYP2C9KDM4EALDH1A1
SCHEMBL29464535 0.77 SCN9A (0.37) MPLCYP1A2CYP2C9KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed